NVAX Novavax, Inc.
Healthcare$10.46+13.57%ClosedMarket Cap: $1.72B
As of 2026-05-26
Valuation
P/E (TTM)
2.95
PEG
0.01
P/B
-10.39
P/S
2.54
EV/EBITDA
-27.73
DCF Value
$-78.02
FCF Yield
-6.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.6%
Operating Margin
-11.2%
Net Margin
-14.7%
ROE
89.7%
ROA
-8.4%
ROIC
-9.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $139.5M | 78.0% | $-15.4M | $-9.5M | $— | — |
| Q4 null | $147.1M | 82.9% | $21.0M | $17.5M | $— | — |
| FY null | $1.12B | 93.7% | $563.3M | $440.3M | $— | — |
| Q3 null | $70.4M | 69.5% | $-178.0M | $-202.4M | $— | — |
| Q2 null | $239.2M | 94.1% | $105.7M | $106.5M | $— | — |
| Q1 null | $666.7M | 97.9% | $515.5M | $518.6M | $— | — |
| Q4 null | $88.3M | 58.5% | $-131.1M | $-81.0M | $— | — |
| FY null | $682.2M | 70.3% | $-248.9M | $-187.5M | $— | — |
| Q3 null | $84.5M | 28.3% | $-134.0M | $-121.3M | $— | — |
| Q2 null | $415.5M | 88.9% | $161.0M | $162.4M | $— | — |
| Q1 null | $93.9M | 48.0% | $-138.7M | $-147.6M | $— | — |
| Q4 2023 | $291.3M | 48.9% | $-183.6M | $-178.4M | $-1.44 | — |